Skip to main content

Table 2 Content of information PIs provided with local and imported anti-hypertensive medications

From: Comparative analysis of package inserts of local and imported antihypertensive medications in Palestine

Criteria A
N = 6 (40% of local PIs)
B
N = 4
(26.67% of local PIs)
C
N = 3
(20% of local PIs)
D
N = 2 (13.33% of local PIs)
Total scores of Local Products N = 15 (42.86% of total PIs) Total scores of Imported Products N = 20 (57.14% of total PIs) Total
N = 35 (100%)
Brand name 6 (100%) 4 (100) 3 (100) 2 (100) 15 (100) 20 (100) 35 (100)
Active ingredient 6 (100) 4 (100) 3 (100) 2 (100) 15 (100) 20 (100) 35 (100)
Inactive ingredients (excipients) 0 (0) 0 (0) 0 (0) 1 (50) 1 (6.6) 20 (100) 21 (60)
Therapeutic class 2 (33.3) 0 (0) 2 (66.6) 2 (100) 6 (40) 19 (95) 25 (71.4)
Mechanism of action 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 6 (30) 6 (17.1)
Indications 6 (100) 4 (100) 3 (100) 2 (100) 15 (100) 20 (100) 35 (100)
Drug dose 0 (0) 1 (25) 1 (33.3) 0 (0) 2 (13.3) 7 (35) 9 (25.7)
Duration of using 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 1 (2.8)
Missing dose 6 (100) 2 (50) 2 (66.6) 2 (100) 12 (80) 17 (85) 29 (82.8)
Maximum dose 0 (0) 1 (25) 1 (33.3) 0 (0) 2 (13.3) 2 (10) 4 (11.4)
Directions for use 6 (100) 4 (100) 3 (100) 2 (100) 15 (100) 20 (100) 35 (100)
Overdose and management 6 (100) 2 (50) 3 (100) 2 (100) 13 (86.6) 20 (100) 33 (94.2)
Warning and precautions 6 (100) 4 (100) 3 (100) 2 (100) 15 (100) 19 (95) 34 (97.1)
Effect on ability to drive and use machines 0 (0) 1 (25) 1 (33.3) 1 (50) 3 (20) 20 (100) 23 (65.7)
Contraindications 6 (100) 2 (50) 3 (100) 2 (100) 13 (86.6) 20 (100) 33 (94.2)
Adverse drug reactions 6 (100) 4 (100) 3 (100) 2 (100) 15 (100) 20 (100) 35 (100)
Drug-drug interactions 6 (100) 4 (100) 3 (100) 2 (100) 15 (100) 20 (100) 35 (100)
Drug-food interactions 1 (16.6) 1 (25) 1 (33.3) 1 (50) 4 (26.6) 19 (95) 23 (65.7)
Pregnancy considerations 6 (100) 4 (100) 3 (100) 2 (100) 15 (100) 20 (100) 35 (100)
Lactation considerations 6 (100) 4 (100) 3 (100) 2 (100) 15 (100) 20 (100) 35 (100)
Pediatric considerations 4 (66.6) 3 (75) 3 (100) 2 (100) 12 (80) 20 (100) 32 (91.4)
Geriatric considerations 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 11 (55) 11 (31.4)
Possibility of tablet splitting 0 (0) 1 (25) 0 (0) 1 (50) 2 (13.3) 15 (75) 17 (48.5)
Possibility of crushing and mixing with food or beverages 4 (66.6) 3 (75) 1 (33.3) 1 (50) 9 (60) 15 (75) 24 (68.5)
Instructions to convert tablets or capsules into liquid forms 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Pharmacokinetic information 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (10) 2 (5.7)
Shelf life 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Storage 6 (100) 4 (100) 3 (100) 2 (100) 15 (100) 20 (100) 35 (100)
Name and address of manufacturers/distributors 6 (100) 4 (100) 3 (100) 2 (100) 15 (100) 19 (95) 34 (97.1)
Date of last revision 0 (0) 0 (0) 0 (0) 1 (50) 1 (6.6) 14 (70) 15 (42.8)
Sources of information 5 (83.3) 2 (50) 1 (33.3) 0 (0) 8 (53.3) 0 (0) 8 (22.8)